Overview of X-Inactivation

In mammals, females have two X chromosomes, while males have only one X and one Y chromosome. If genes on both X chromosomes are expressed at the same time, twice as many genes are expressed on the X chromosome in females as in males, which can lead to abnormal development or disease. To avoid this, mammals have evolved a mechanism called X-inactivation. X-inactivation refers to the random silencing of one of the two X chromosomes in the somatic cells of female individuals so that the gene expression on the X chromosome is the same as that of male individuals. This silencing is achieved by highly condensing the X chromosome into a structure called a Barr body. Barr bodies are inherited from daughter cells during cell division, so which X chromosome is silenced in each cell is fixed. In this way, only one X chromosome is active in each cell of females, just like males. This mechanism, called dosage compensation, ensures that gene expression on the X chromosome is balanced between the sexes.

The process of X-inactivation may be abnormal or incomplete, resulting in the silencing or abnormal expression of some genes on the X chromosome, thereby affecting normal physiological functions or development. Some diseases are caused by abnormalities in the number or structure of the X chromosome, such as Turner syndrome and Klinefelter syndrome. Some diseases are caused by mutations or deletions of genes on the X chromosome, such as Rett syndrome and X-linked ichthyosis. Some diseases are caused by the randomness of X-inactivation, such as fragile X syndrome. The incidence and severity of these disorders also vary between males and females, depending on the pattern and rate of X-inactivation.

Turner Syndrome

Turner syndrome is a genetic disorder that occurs only in females and is caused by a missing or partial deletion of the X chromosome. Patients may present with a variety of symptoms and features, including short stature, ovarian insufficiency, and heart defects. The diagnosis of Turner syndrome can be made before birth (antenatal), in infancy, or early childhood. Prenatal diagnosis can be done with cell-free DNA screening or an ultrasound of a blood sample from the mother. A diagnosis in infancy or early childhood can be established by observing physical characteristics and performing chromosomal analysis. There is currently no cure for Turner syndrome, but growth hormone therapy, estrogen replacement therapy, assisted reproductive technology, cardiac surgery, and other measures can be used to relieve symptoms and prevent complications. Regarding gene therapy programs, there is currently no effective method for Turner syndrome. But there are some experimental studies underway, such as using artificial chromosomes to complement missing genes on the X chromosome. These methods need further verification and improvement before they can be applied clinically.

Klinefelter Syndrome

Klinefelter syndrome is a congenital genetic disease caused by males born with one or more extra X chromosomes. This condition is not inherited but results from random genetic errors that occur when the egg or sperm are formed or after fertilization. Klinefelter syndrome is common, occurring in 1 in 500 to 1 in 1000 males born in Australia each year. Klinefelter syndrome affects the production of the male hormone testosterone, which affects the development of male characteristics. Symptoms of Klinefelter syndrome vary from person to person and may be mild in some people and severe in others. In general, Klinefelter syndrome can lead to problems such as inadequate male characteristics, developmental delays, infertility, and other health risks at various stages from infancy to adulthood. At present, only testosterone replacement therapy, counseling, surgery and assisted reproductive technology can be used to improve the symptoms and quality of life of patients with Klinefelter syndrome. There are currently no gene therapy options for Klinefelter syndrome. But there are some ongoing or planned clinical trials exploring the use of gene-editing technologies such as CRISPR-Cas9 to repair or delete genes on the extra X chromosome. These trials are in their early stages and have not yet demonstrated their safety and efficacy.

Rett Syndrome

Rett syndrome is a rare inherited neurodevelopmental disorder that primarily affects females and causes abnormal brain development that affects motor, language, and cognitive abilities. Rett syndrome occurs due to a mutation in the MECP2 gene on the X chromosome, resulting in a defect in the function of the protein encoded by this gene. This protein plays an important role in regulating the expression of other genes and the transmission of signals between neurons. Symptoms of Rett syndrome usually appear in infants between 6 months and 18 months of age and manifest as deterioration of motor and language skills, loss of hand function, typical repetitive hand movements (such as flapping, rubbing, or squeezing), slow head and body growth, abnormal gait, seizures, digestive problems, etc. The severity of Rett syndrome varies from person to person. Some people can walk and talk, while others are completely dependent on others for their care.

Rett syndrome is a complex and diverse neurodevelopmental disorder that requires multidisciplinary collaboration to provide optimal diagnosis and treatment. At present, the treatment of Rett syndrome is mainly based on supportive and palliative measures for symptoms. Treatment options may include physical therapy, speech therapy, behavioral therapy, medication, nutritional supplements, surgery, and more. Gene therapy, a potential treatment for Rett syndrome, aims to restore or replace the MECP2 gene or protein, thereby restoring brain function. Several gene therapy options are in clinical trials or pre-studies, including the use of AAV vectors to deliver normal MECP2 genes into neurons, the use of CRISPR/Cas9 technology to repair mutated MECP2 genes, and the use of drugs to activate normal MECP2 genes on the silenced X chromosome. MECP2 gene. These solutions all have certain challenges and risks and need further verification and optimization.

X-linked Ichthyosis

X-linked ichthyosis is an inherited skin disorder caused by a deficiency of ester sulfatase (STS) that affects approximately 1 in 2,000 to 6,000 males. STS is an enzyme involved in the metabolism of cholesterol sulfate in the skin. STS deficiency leads to the accumulation of cholesterol sulfate in the superficial layers of the skin, leading to skin barrier dysfunction and the retention of epidermal cells (keratinocytes), forming the typical scales. X-linked ichthyosis occurs due to a deletion or mutation of the STS gene. The STS gene is located on the Xp22.3 segment of the X chromosome. Thus, the syndrome is an X-linked genetic disorder that affects males and females differently. The 23rd pair of chromosomes is often referred to as the "sex chromosomes". Symptoms of X-linked ichthyosis include dry, scaly skin, especially on the back of the neck, trunk, and extremities. The scales are usually dark or grayish in color, larger than 4 mm in diameter, and cling to the underlying layers of the skin. The face, scalp, palms, and soles are usually unaffected. Symptoms of X-linked ichthyosis usually appear at birth or within 6 months of life and improve during the summer. X-linked ichthyosis usually does not cause other major medical problems other than skin scaling. However, some patients may have complications such as corneal opacity, cryptorchidism, and cardiac arrhythmia. The current treatment of X-linked ichthyosis is mainly aimed at relieving skin symptoms. The goal of gene therapy against X-linked ichthyosis is to introduce normal STS genes into damaged cells or tissues, restore their functions, and correct metabolic disorders. However, this has not been used in clinical treatment.

Fragile X Syndrome

Fragile X syndrome is an inherited intellectual disability caused by a CGG triplet repeat expansion of the FMR1 gene on the X chromosome. This genetic variant causes the FMR1 gene to be silenced (methylated), resulting in a lack of a protein (FMRP) that is necessary for the normal development of neuronal connections. Symptoms of fragile X syndrome include intellectual disability, an elongated face, large or protruding ears, dexterous fingers, large testicles (mecrorchidism), and low muscle tone. About one-third of patients have features of autism spectrum disorder, such as difficulties with social interaction and language delays. Hyperactivity is common, and seizures occur in approximately 10% of patients. Men are usually more severely affected than women. The diagnosis of fragile X syndrome requires genetic testing to determine the number of CGG repeats in the FMR1 gene. Under normal circumstances, the number of repetitions is between 5 and 40; when the number of repetitions exceeds 200, fragile X syndrome will appear. When the number of repeats is between 55 and 200, it is called a premutation. Women with a premutation have a higher risk of having an affected child. Testing for prevariant carriers can provide genetic counseling.

There is currently no cure for fragile X syndrome. Early intervention is recommended, as it provides the greatest opportunity to develop well-rounded skills. These interventions may include special education, speech therapy, physical therapy, or behavioral therapy. Medications may be used to treat associated seizures, mood problems, aggressive behavior, or ADHD. The gene therapy program for fragile X syndrome is still in the experimental stage and has not yet entered clinical trials. Some possible strategies include using small-molecule drugs to activate the FMR1 gene, using the CRISPR/Cas9 system to repair the FMR1 gene, using AAV vectors to deliver FMRP protein to neurons, etc. These methods need to be further verified for their safety and effectiveness.

References

  1. Gravholt CH, et al. Turner syndrome: mechanisms and management. Nat Rev Endocrinol. 2019 Oct;15(10):601-614.
  2. Steiner M, et al. Turner Syndrome: An Update. Adv Pediatr. 2022 Aug;69(1):177-202.
  3. Gravholt CH, et al. Clinical practice guidelines for the care of girls and women with Turner syndrome: proceedings from the 2016 Cincinnati International Turner Syndrome Meeting. Eur J Endocrinol. 2017 Sep;177(3):G1-G70.
  4. Bonomi M, et al. Klinefelter syndrome (KS): genetics, clinical phenotype and hypogonadism. J Endocrinol Invest. 2017 Feb;40(2):123-134.
  5. Bearelly P, et al. Recent advances in managing and understanding Klinefelter syndrome. F1000Res. 2019 Jan 28;8:F1000 Faculty Rev-112.
  6. Fainberg J, et al. Fertility management of Klinefelter syndrome. Expert Rev Endocrinol Metab. 2019 Nov;14(6):369-380.
  7. Kyle SM, et al. Rett syndrome: a neurological disorder with metabolic components. Open Biol. 2018 Feb;8(2):170216.
  8. Vidal S, et al. Genetic Landscape of Rett Syndrome Spectrum: Improvements and Challenges. Int J Mol Sci. 2019 Aug 12;20(16):3925.
  9. Banerjee A, et al. Towards a better diagnosis and treatment of Rett syndrome: a model synaptic disorder. Brain. 2019 Feb 1;142(2):239-248.
  10. Spagnoli C, et al. Rett Syndrome Spectrum in Monogenic Developmental-Epileptic Encephalopathies and Epilepsies: A Review. Genes (Basel). 2021 Jul 28;12(8):1157.
  11. Wren GH, et al. X-linked ichthyosis: New insights into a multi-system disorder. Skin Health Dis. 2022 Oct 17;2(4):e179.
  12. Liaugaudienė O, et al. X-linked ichthyosis: differential diagnosis of low maternal oestriol level. J Obstet Gynaecol. 2014 Nov;34(8):737-9.
  13. Salcedo-Arellano MJ, et al. Fragile X syndrome: clinical presentation, pathology and treatment. Gac Med Mex. 2020;156(1):60-66. English.
  14. Protic DD, et al. Fragile X Syndrome: From Molecular Aspect to Clinical Treatment. Int J Mol Sci. 2022 Feb 9;23(4):1935.
  15. Richter JD, et al. The molecular biology of FMRP: new insights into fragile X syndrome. Nat Rev Neurosci. 2021 Apr;22(4):209-222.
For research use only. Not intended for any clinical use.